|
J Biol Chem, Vol. 275, Issue 16, 11603-11609, April 21, 2000
Exploration of the Drosophila Acetylcholinesterase
Substrate Activation Site Using a Reversible Inhibitor (Triton X-100)
and Mutated Enzymes*
Véronique
Marcel ,
Sandino
Estrada-Mondaca §,
Frédéric
Magné ,
Jure
Stojan¶,
Alain
Klaébé , and
Didier
Fournier
From the Laboratoire de Synthèse et
Physicochimie des Molécules d'Intérêt Biologique,
ESA 5068, Groupe de Biochimie des Protéines, Université
Paul Sabatier, 31062 Toulouse, France and the ¶ Institute of
Biochemistry, Medical Faculty, University of Ljubljana, Vrazov trg 2, 1000 Ljubljana, Slovenia
 |
ABSTRACT |
Cholinesterases are activated at low substrate
concentration, and this is followed by inhibition as the level of
substrate increases. However, one of these two components is sometimes
lacking. In Drosophila acetylcholinesterase, the two phases
are present, allowing both phenomena to be studied. Several kinetic
schemes can explain this complex kinetic behavior. Among them, one
model assumes that activation results from the binding of a substrate molecule to a non-productive site affecting the entrance of a substrate
molecule into the active site. To test this hypothesis, we looked for
an inhibitor competitive for activation and we found Triton X-100.
Using organophosphates or carbamates as hemisubstrates, we showed that
Triton X-100 inhibits or increases phosphorylation or carbamoylation of
the enzyme. In vitro mutagenesis of the residues lining the active site gorge allowed us to locate the Triton X-100 binding site at the rim of the gorge with glutamate 107 playing the
major role. These results led to the hypothesis that substrate binding
at this site affects the entrance of another substrate molecule into
the active site cleft.
 |
INTRODUCTION |
Cholinesterases belong to the family of serine hydrolases.
In vertebrates, they are present in two forms: acetylcholinesterase (AChE,1 EC 3.1.1.7), which
hydrolyzes the neurotransmitter acetylcholine in order to stop nervous
impulse transmission at the cholinergic synapses, and
butyrylcholinesterase (EC 3.1.1.8), for which the physiological role is
not well known. Two substrate binding sites are present on these
enzymes: the catalytic site, located at the bottom of a gorge (the
so-called "catalytic gorge"; Ref. 1), and a peripheral site that
can bind various ligands bearing a quaternary ammonium (2, 3).
Hydrolysis of the substrate occurs in three steps (1, 4-6): (i)
formation of an enzyme-substrate complex, (ii) acylation of the enzyme,
and (iii) deacylation by hydrolysis. To analyze the first two steps, we
can use a hemisubstrate: an organophosphate. Phosphorylation of the
active serine by this compound can be considered as irreversible since
dephosphorylation is a very slow step, the half-life for hydrolysis of
the phosphoryl enzyme being measured in days (7).
In insects, only one form of the enzyme, called acetylcholinesterase,
is present in the central nervous system. While in vertebrates, AChE is
inhibited by excess substrate and butyrylcholinesterase is activated by
low substrate concentrations (8), insect AChE combines both types of
kinetic behavior, suggesting that the two phenomena are independent and
result from different bindings, and not from different manifestations,
acceleration or inhibition of catalysis, of the same binding (9). In a
recent paper (10), we proposed a kinetic scheme to describe this
complex kinetic behavior. The scheme suggests the existence of a high
affinity non-productive site for the substrate. The binding of a
substrate molecule to this site has the consequence of slowing down the positioning of a second substrate molecule at the active site, resulting in an apparent activation of the enzyme.
In order to precisely analyze the activation phenomenon observed, we
searched for a reversible inhibitor that binds only to the activation
site. Among several AChE inhibitors tested: choline, tetramethylammonium, edrophonium (11), propidium, and Triton X-100,
only the latter affected activation by the substrate. Triton X-100 is a
non-ionic detergent that is widely used to solubilize membrane-bound proteins, but it has also been described to inhibit cholinesterase activity (12-14). We used this molecule in inhibition experiments and found that it is in competition with the substrate for
binding at the activation site.
Comparing the phosphorylation rate constants of several mutated
enzymes, we saw that Triton X-100 binds at the rim of the gorge and, as
a consequence, inhibits the enzyme activity by hindering access to the
entrance of the active site, thus decreasing the acylation step.
 |
EXPERIMENTAL PROCEDURES |
Chemicals and Source of Enzyme--
Triton X-100, polyethylene
glycol, reduced Triton X-100, edrophonium, and propidium were from
Sigma. As Triton X-100 is a mixture of two chain lengths
(n = 9 and 10), its concentration will be expressed in
g·liter 1. Truncated cDNA encoding soluble AChE of
Drosophila melanogaster was expressed with the baculovirus
system (15). Secreted AChE were purified and stabilized with 1 mg·ml 1 bovine serum albumin according to
Estrada-Mondaca and Fournier (16). The concentration of the enzymes was
determined by active site titration using
7-(methylethoxyphosphinyloxy)-1-methylquinolinium iodide, which was
synthesized as described by Levy and Ashani (17). Residue numbering
follows that of the precursor (18); correspondence with the
Torpedo AChE sequence was done according to Stojan (19) and
is given in parentheses in Table I.
Kinetics of Substrate Hydrolysis--
Kinetics were followed at
25 °C in 25 mM phosphate buffer, pH 7. Hydrolysis of
acetylthiocholine iodide was studied spectrophotometrically at 412 nm
using the method of Ellman et al. (20), at substrate concentrations from 2 µM to 200 mM in 1-cm
path length cuvettes using a Safas DES spectrophotometer. Activity was
measured for 1 min, from 10 to 70 s after addition of the enzyme
to the mixture. kobs is the number of micromoles
of product formed/s/µmol of enzyme.
Enzyme inhibition by Triton X-100 was studied at different inhibitor
concentrations (0-10 g·liter 1). The rate data were
analyzed by multiple non-linear regression using non-linear global
optimization based on simulated
annealing.2
The rate constant of enzyme phosphorylation or carbamoylation was
determined by the dilution method of Aldridge (21); at time 0, the
organophosphorous compound or the carbamate was added to enzyme
solutions (~10 nM) in 25 mM phosphate buffer,
pH 7, with 1 mg·ml 1 bovine serum albumin. Inhibition of
the enzyme with time was followed by measuring the free enzyme
concentration after dilution in the presence of substrate. The
inhibition followed pseudo-first order kinetics since the concentration
of the irreversible inhibitor was always at least 10-fold higher than
the enzyme concentration.
|
(Eq. 1)
|
[E] and [E]0 are the
enzyme concentrations at times t and 0, respectively and
[PX0], the organophosphate (or carbamate)
concentration. The experimental phosphorylation (or carbamoylation)
rate constants (ki(obs)) were estimated in the
presence of different concentrations of Triton X-100, reduced Triton
X-100, or polyethylene glycol (0-10 g·liter 1).
Determination of Critical Micellar Concentration for Triton
X-100--
The critical micellar concentration (CMC) of Triton X-100
was determined in 25 mM phosphate buffer at pH 7 and
25 °C, using the method described by Ross and Olivier (22).
Briefly, the Triton X-100 was mixed at various concentrations with a 30 mg·liter 1 iodide solution. Then the absorbance was
determined at 360 nm. The plot of OD versus [Triton X-100]
is linear below and above the CMC with different slopes. The point of
intersection of the two extrapolated straight lines yields the CMC.
Molecular Modeling--
Building and optimization of
three-dimensional models of Triton X-100/Drosphila AChE were
performed on a Silicon Graphics IRIS workstation using Biosym modeling
software with a Drosophila AChE scheme built by homology
with the Torpedo enzyme (19) with five layers of surrounding
water molecules. Docking was performed using a distance constraint
between the iso-octyl part of Triton X-100 and the amino acid at
position 107. Molecular dynamics calculations were carried out as
follows; the structure was equilibrated at 300 K for 20 ps, followed by
subsequent 10-ps dynamic runs at 300 K. Second, after minimization, the
same sequence was applied without any constraints on the whole system.
 |
RESULTS |
Inhibition of Substrate Hydrolysis by Triton
X-100--
Acetylthiocholine hydrolysis by Drosophila AChE
was studied in the presence of different concentrations of Triton X-100
(0-10 g·liter 1). As opposed to electric eel AChE (12),
the activity of the enzyme in the presence of Triton X-100 was found to
be linear with time. Thus, Triton X-100 was considered to be a
reversible inhibitor. Several kinetic models can be used to describe
substrate hydrolysis by the Drosophila enzyme (9). The one
proposed by Cauet et al. (23) and reduced to Scheme 1 describes activation and inhibition by substrate and leads to the
determination of kinetic parameters (10).
E is the free enzyme, EA the acylated
enzyme, and SE represents the binding of a substrate
molecule onto the activation site. ka represents
the bimolecular rate constant for acylation and kcat the rate constant for deacylation.
a and b coefficients represent the effect of the
activation site occupation by a substrate molecule on deacylation and
acylation respectively. Ks and
K's represent the affinity of the activation
site for a substrate molecule. This scheme was chosen because it can be
further reduced when the deacylation step is ignored, i.e.
when organophosphorous compounds are used as substrates instead of
acetylcholine (see below).
Inhibition by Triton X-100 (Fig. 1)
was analyzed assuming that two molecules of Triton X-100 can bind at
two sites, a catalytic site and a peripheral site, whether the enzyme
is free or acetylated, as tetramethylammonium does (11). We derived a
complete scheme, and the resulting kinetic equation was used to
simultaneously analyze 11-pS curves obtained with Triton X-100
concentrations varying from 1 mg·liter 1 to 100 g·liter 1. In a second step, we eliminated inoperative
constants and the scheme became reduced to Scheme 2 without any
decrease of goodness of fit.
In this scheme, the ternary complex (two inhibitor molecules bound
to the enzyme) is not taken into account. Triton X-100 binds
competitively with the substrate at the non-productive, or activation,
site. TE represents the binding of a Triton X-100 molecule
onto the activation site; c and d represent the
effects of activation site occupation by Triton X-100 on acylation and deacylation, respectively.
|
(Eq. 2)
|
Non-linear fit allowed the estimation of some constants: affinity
of Triton X-100 for the free enzyme, Kt = 0.033 ± 0.003 g·liter 1; effect of Triton X-100
binding on acylation, c = 0.136 ± 0.04. However,
the affinity of Triton X-100 for acetylated enzyme,
K't, was above 10 g·liter 1 and
therefore could not be estimated and the effect of Triton X-100 on
deacetylation, d, correlated with K't
could not be determined either.

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 1.
pS activity curves for acetylthiocholine
hydrolysis by Drosophila AChE, in the presence of
different concentrations of Triton X-100. The curves were obtained
by fitting curves from 0 to 10 g·liter 1 of Triton X-100
to Equation 2, corresponding to Scheme 2.
|
|
Thus, Triton X-100 is a competitive inhibitor of activation by the
substrate. According to Scheme 2, Triton X-100 decreases acetylation of
the enzyme to 13.6%. To test this scheme, we used hemisubstrates,
substrates for which the second step of the reaction (dealkylation or
dephosphorylation) does not take place during the time of the experiment.
Effect of Triton X-100 on Phosphorylation by Malaoxon--
We
observed an inhibition of phosphorylation by malaoxon with increasing
concentrations of Triton X-100, up to a plateau (Fig. 2A). Initially, we thought
that malaoxon was trapped in the hydrophobic core of Triton X-100
micelles and, consequently, the concentration of the organophosphate
available for the enzyme would be overevaluated. However, two
observations led us to reject this hypothesis. First, phosphorylation
was already diminished at a concentration below the CMC, 0.28 g·liter 1 in the experimental conditions used. Second,
no effect of Triton X-100 on phosphorylation was detected with the
Torpedo AChE (Fig. 2B). Thus, both results
suggest that inhibition of the phosphorylation constant by Triton X-100
originated from an interaction of Triton X-100 with the
Drosophila enzyme and not from an artifact. Phosphorylation can be analyzed with Scheme 3, which is identical to Scheme 2 when
deacetylation of the enzyme is negligible.
|
|
|
|
As the dilution method was used to phosphorylate the active site,
it was not possible to test a large range of organophosphate concentrations. Indeed, above 3 µM, inhibition was too
fast and, below 0.1 µM, the kinetics were no longer
pseudo first-order since the free inhibitor concentration cannot be
considered as constant. As a consequence, it was not possible to
estimate the affinity of malaoxon for the non-productive site
(Kpx) or the effect of occupation of the
non-productive site on phosphorylation (b). Then, Scheme 3 was reduced to Scheme 4, where ki corresponds to the overall inhibition constant.
|
(Eq. 3)
|
The phosphorylation rates observed (kobs)
were determined at different concentrations of Triton X-100 (0-10
g·liter 1) allowing the estimation of Triton X-100
affinity (Kt) and the effect of Triton X-100 on
phosphorylation (c): Kt = 0.06 ± 0.02 g·liter 1 and c = 0.18 ± 0.04. These estimations are in agreement with c and
Kt values obtained by measuring
acetylthiocholine hydrolysis inhibition according to Scheme 3.

View larger version (14K):
[in this window]
[in a new window]
|
Fig. 2.
Variation of the phosphorylation rate
constant (ki(obs)) by
malaoxon obtained with wild type Drosophila AChE and
Torpedo AChE, versus concentration of
Triton X-100.
|
|
Triton X-100 inhibits phosphorylation of the active site by malaoxon,
suggesting that activation of substrate hydrolysis results from
inhibition of active site acetylation since Triton X-100 binds at the
activation site.
Effect of Triton X-100 on Phosphorylation or Carbamoylation by
Various Molecules--
Scheme 4 was used to study the effect of Triton
X-100 on other hemisubstrates. The results are presented in Table
I. It appears that Triton X-100 affects
phosphorylation or carbamoylation of the serine; for some compounds
such as paraoxon, it decreases the phosphorylation rate but for other
compounds, such as aldicarbe or metamidophos, Triton X-100
significantly increases the phosphorylation or carbamoylation rate.
Thus, binding of a substrate molecule at the activation site may either
increase or decrease the acylation of the enzyme.
View this table:
[in this window]
[in a new window]
|
Table I
Kinetic parameters obtained for the inhibition of phosphorylation or
carbamoylation by Triton X-100 of wild type enzyme
Constants are analyzed using Equation 3.
|
|
Competition of Triton X-100 Inhibition by Inhibitors Specific for
Anionic and Peripheral Sites--
Inhibition of phosphorylation by
Triton X-100 was studied in the presence of two inhibitors specific for
anionic and peripheral sites, edrophonium or propidium. The data were
analyzed with Scheme 5, which is an extension of Scheme 4.
|
(Eq. 4)
|
I represents edrophonium or propidium, and T indicates the Triton
X-100. Both inhibitors decreased the phosphorylation rate; results of
the fit are presented in Fig. 3. With
propidium, including the ternary complex (ITE) did not
improve the fit, suggesting that the two inhibitors, Triton X-100 and
propidium, are competitive, i.e. that they cannot bind
simultaneously to the enzyme; their respective binding sites are
overlapping. By contrast, simultaneous binding of edrophonium and
Triton X-100 to the enzyme was revealed because
K't was operative for the fit, suggesting that
the two binding sites are different. Taking in account that propidium binds at the rim of the active site gorge while edrophonium binds at
the bottom of the gorge, this suggests that Triton X-100 binds at the
rim of the gorge.
Triton X-100 Inhibition of Mutated Enzymes--
In order to obtain
information on the Triton X-100 binding site, we analyzed the
phosphorylation of several mutated enzymes in the presence of Triton
X-100 (Fig. 4).
Kt, ki, and c
were determined (Table II). The mutations
E107Y and E107W strongly increased the affinity of Triton X-100;
mutants W359L and D413G moderately increased the affinity while mutants
Y412A, E107K, and Y109K slightly decreased the affinity of Triton
X-100. On the other hand, some mutations affected the c
factor. When classified following their effects, mutations E107W,
E107Y, and D413G increased inhibition by Triton X-100 while mutations
W359L, Y362A, Y111Q, and Y412A slightly decreased the effect of Triton
X-100.
View this table:
[in this window]
[in a new window]
|
Table II
Kinetic parameters obtained for the inhibition of malaoxon
phosphorylation by Triton X-100 with various mutated enzymes
Constants are analyzed using equation 3.
|
|
Effect of Triton X-100 Analogues--
Triton X-100 includes a
hydrophobic part, the aromatic ring, coupled with a hydrocarbon chain
and a hydrophilic part, the polyethylene glycol chain. To evaluate the
involvement of each part of the molecule in its recognition by the
activation site, we studied the inhibition of the wild type enzyme by
malaoxon in the presence of polyethylene glycol or reduced Triton
X-100. It was ground that reduced Triton X-100 presents the same
affinity as Triton X-100, while the affinity of polyethylene glycol was much lower (KPEG = 2.64 ± 1.76 g·liter 1).
 |
DISCUSSION |
Inhibition by Triton X-100--
Triton X-100 is a detergent widely
used to solubilize membrane-anchored proteins such as insect
cholinesterase, which is linked to the membrane via a glycolipid (24,
25). Devonshire (26) noted that Triton X-100 increased the apparent
Km for the substrate, but activation was not
evidenced because the presence of the glycolipid anchor did not allow
complete elimination of the detergent from the solution. In
vitro expression of a soluble cholinesterase, devoid of any lipid
anchor, allowed kinetic studies to be performed in the absence of
detergent, activation to be demonstrated at low substrate concentration
(9), and the effect of Triton X-100 to be studied. It appears that this
molecule is a competitive inhibitor of activation with a dissociation
constant of 0.033 g·liter 1.
Since kinetic models resulting from analysis of pS curves predicted
that apparent activation may result from an increase or a decrease of
the acylation rate constant depending on the scheme chosen (9, 10), we
looked for a hemisubstrate, for which the second step, deacylation, is
negligible. As phosphorylation by organophosphate is considered to be
equivalent to acylation by acetylcholine, organophosphates and
carbamates were used to evaluate the effect of Triton X-100 on the
"acylation" step. As previously observed by Devonshire (26), we
found a decrease of the phosphorylation rate constant with malaoxon in
the presence of Triton X-100; however, using other hemisubstrates, we
found that Triton X-100 can either increase or decrease the acylation rate.
Localization of the Triton X-100 Binding Site--
Triton X-100
increases or only partially inhibits phosphorylation and thus does not
compete with irreversible inhibitors at the productive site. This is
the first evidence that Triton X-100 most probably binds to a
peripheral site. As a reference, edrophonium, which binds at the
productive site, totally suppresses phosphorylation by malaoxon
(a1 is not significantly different from zero). However, this result does not give information about the location of this peripheral site. Binding of Triton X-100 and propidium were
competitive, suggesting that the ternary complex, Triton
X-100-propidium-enzyme, does not exist. So the binding sites for Triton
X-100 and propidium are identical or overlapping.
In vitro mutagenesis was used to locate the Triton X-100
binding site independently. Triton X-100 inhibition of phosphorylation by malaoxon was observed with the Drosophila enzyme, but
Triton X-100 did not significantly affect phosphorylation of
Torpedo enzyme. We first hypothesized that phosphorylation
inhibition came from one of the residues that differs between the two
enzymes. Several mutations were chosen on residues lining the active
site gorge in order to mimic the Torpedo enzyme: E107Y
(Y70); R108V (V71); Y109D (D72); Y111Q (Q74); V356D (D276); L366F
(F288); Y408F (F330); V356D (D276), and D413G (G335). However, these
single mutations did not abolish the effect of Triton X-100, suggesting that either another residue is effective for Triton X-100 inhibition or
that the differential behavior of the two enzymes originates from a
combination of several mutations. Mutations inside the gorge (G303A,
E275G, W309G, W121A, and F368L) did not significantly change the
affinity of Triton X-100 (Kt) compared with the
wild type, confirming that Triton X-100 does not enter the active site gorge (Table I). Among the mutations located at the rim of the gorge,
E107Y and E107W increased the affinity for Triton X-100 10-fold. This
suggests that Triton X-100 binds at the entrance of the gorge and that
residue Glu-107 forms a major part of this site.
Glu-107 has been shown to belong to the peripheral anionic site but is
not conserved in the ChE family; at this position, we can find a
methionine in Bungarus fasciatus AChE, a tyrosine in
Torpedo and human AChEs, or an asparagine in human
butyrylcholinesterase. In vitro mutagenesis of AChE from
vertebrates has shown that this residue affects the binding of
peripheral site ligands propidium, gallanine, and tubocurarine, as well
as the binding of bis-quaternary ligands such as decamethonium and
BW284C51, which bind at both the active and peripheral sites (6,
27-29).
Some mutations located in the proximity of Glu-107 (W359L, D413G, and
R108V; see Fig. 4) also affected the affinity for Triton X-100, but to
a lesser extent (Table I). This suggests that other residues in the
vicinity of Glu-107 participate in Triton X-100 binding. Among them are
Trp-359, Asp-413, and Arg-108. The first, Trp-359, has been shown to be
one of the most important residues for the binding of several ligands
such as propidium in vertebrate AChE (27, 30, 31). Similarly, this
residue is important for propidium binding on Drosophila
AChE; the dissociation constant of propidium (8 nM for the
wild type AChE) increases to 12 µM for the W359L mutant.
As mutation W359L only slightly affects the binding of Triton X-100, as
binding of Triton X-100 and propidium are competitive, and as the two
residues, Glu-107 and Trp-359, are close, we can conclude that the two
peripheral sites partially overlap.
Interaction of Triton X-100 with the Activation Binding
Site--
Reduced Triton X-100 had the same affinity as Triton X-100
for the activation site; interactions between the aromatic moiety of Triton X-100 and an aromatic residue of the active site can thus be
ruled out. Mutagenesis of residue Glu-107 suggests that the interaction
is mainly hydrophobic according to the hydrophobicity indices of Hopp
and Woods (32). Indeed, the replacement of glutamate by a more
hydrophobic residue (tyrosine, tryptophan, or leucine) increases the
Triton X-100 affinity for the protein, whereas a residue that presents
approximately the same hydrophobicity as glutamate, a lysine, does not
modify the affinity. This result is tentatively illustrated in Fig.
5. Triton X-100 has been made to dock on
E107Y mutant because it displayed the highest affinity for Triton X-100
(Table I), and we mimicked the hydrophobic interaction by imposing a
distance constraint between the iso-octyl moiety and the aromatic ring
for the first minimization; this constraint was removed for the
following steps.

View larger version (36K):
[in this window]
[in a new window]
|
Fig. 5.
Proposed binding orientation of Triton X-100
at the rim of the active site gorge, in hydrophobic interaction with
tyrosine 107; water molecules are not shown. A, side view;
B, upside view.
|
|
Does this interaction between Triton X-100 and the enzyme provide
information for the interaction of acetylcholine at the peripheral
site? Binding of the two molecules is competitive, but this does not
necessarily imply they both interact with the same site via the same
interaction; it only suggests that the two sites overlap. However, if
the two sites are identical, it must be remembered that the ammonium
moiety of acetylcholine is buried inside a cloud of methyls and behaves
like a positively charged hydrophobic domain as shown by Fraenkel
et al. (33), when solving the conformations of
d-tubocurarine, free or bound to a recombinant cholinergic
binding site. As a consequence, the attraction of the substrate to the
peripheral site can be electrostatic due to the anionic moiety of the
glutamate, and binding can be enforced by hydrophobic interactions as
for Triton X-100.
Effect of Triton X-100 Binding at the Activation Site--
Triton
X-100 binding at the rim of the active site affects the acylation rate
constant. Three, not mutually exclusive, interpretations can be proposed.
First, Triton X-100 binding at the rim of the gorge modifies the active
site conformation as do peripheral site ligands. Berman et
al. (34) showed conformational changes of AChE following binding
of peripheral site ligands by methylphosphono-AChE fluorescence and
circular dichroism. Studies with mutated proteins confirmed this
hypothesis since binding of ligands to the peripheral site, affects the
Trp-84 orientation (6, 35). The hypothesis of a conformation change
induced by Triton X-100, affecting acylation of the substrate, cannot
be rejected or confirmed with the data presented here.
In the second hypothesis, Triton X-100 affects enzyme phosphorylation
by steric hindrance at the entrance of the active site gorge. This
hypothesis appears to have the greatest weight considering the position
of the Triton X-100 binding site at the rim of the gorge, and the
bulkiness of the Triton X-100 molecule. This explanation has been
proposed by Szegletes et al. (37) for binding of another inhibitor to the peripheral site. Analysis of the effects of mutations on the c value, which expresses the Triton X-100 effect,
corroborates this steric effect hypothesis. Indeed, the E107W mutation
narrows the active site gorge and thus increases the effect of Triton X-100 on phosphorylation by malaoxon (c = 0.01). On the
other hand, W359L, Y362A, Y111Q, and Y412A enlarge the active site
gorge and thus decrease the effect of Triton X-100 on the
phosphorylation rate (c > 0.4).
A third interpretation involves the role of the peripheral site for
substrate hydrolysis, taking into account that Triton X-100 and
substrate binding at the peripheral site are competitive. Szegletes
et al. (37) assumed that the primary role of the AChE peripheral site is to accelerate the hydrolysis of acetylcholine at low
substrate concentrations, so accordingly we can hypothesize that the
function of the activation binding site would be to attract the
substrate molecule in solution, which would be suitably positioned to
reach the catalytic site at the bottom of the gorge. The peripheral site helps direct the substrate to the active site. Inhibition of
Triton X-100 at the rim of the gorge would compete with the initial
binding of substrate and result in inhibition at low substrate concentration (see Fig. 1). Analysis of the effect of mutations at
position 107 on malaoxon phosphorylation is in agreement with this
interpretation. Actually, with the four amino acids modified at this
position, a correlation exists between Triton X-100 affinity and
phosphorylation (Fig. 6). As Triton X-100
affinity represents substrate affinity at the non-productive site and
as phosphorylation represents acylation of the substrate, the
correlation between substrate affinity and acylation suggests that an
increase of affinity for the substrate at the rim of the gorge
increases acylation.

View larger version (13K):
[in this window]
[in a new window]
|
Fig. 6.
Relation between affinity for Triton X-100
and phosphorylation constant by malaoxon for various amino acids
present at position 107.
|
|
 |
FOOTNOTES |
*
This work was supported in part by grants from INSERM
(Programme Environnement et Santé), DGA (Programme d'Étude
Amont, Décontamination), CEE (Occurrence of Toxic Cyanobacteria
Waterblooms Program), CNRS (GDR 1105), and INRA (Genome Project).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
Recipient of a doctoral fellowship from Consejo Nacional de Ciencia
y Tecnologia, Mexico.
To whom correspondence should be addressed: Université
Paul Sabatier, Bat. 4 R3, 31062 Toulouse, France. Fax:
33-5-61-55-69-10; E-mail: fournier@cict.fr.
2
J. Czaplicki, V. Marcel, and D. Fournier,
manuscript in preparation.
 |
ABBREVIATIONS |
The abbreviations used are:
AChE, acetylcholinesterase;
CMC, critical micellar concentration;
pS, product
Substrate.
 |
REFERENCES |
| 1.
|
Sussman, J. L.,
Harel, M.,
Frolow, F.,
Oefner, C.,
Goldman, A.,
Toker, L.,
and Silman, I.
(1991)
Science
253,
872-878[Abstract/Free Full Text]
|
| 2.
|
Changeux, J. P.
(1966)
Mol. Pharmacol.
2,
369-392[Abstract/Free Full Text]
|
| 3.
|
Roufogalis, B. D.,
and Quist, E. E.
(1972)
Mol. Pharmacol.
8,
41-49[Abstract/Free Full Text]
|
| 4.
|
Wilson, I. B.,
and Cabib, E.
(1956)
J. Am. Chem. Soc.
78,
202-207[CrossRef]
|
| 5.
|
Quinn, D.
(1987)
Chem. Rev.
87,
955-979[CrossRef]
|
| 6.
|
Barak, D.,
Kronman, C.,
Ordentlich, A.,
Ariel, N.,
Bromberg, A.,
Marcus, D.,
Lazar, A.,
Velan, B.,
and Shafferman, A.
(1994)
J. Biol. Chem.
269,
6296-6305[Abstract/Free Full Text]
|
| 7.
|
Rosenberry, T. L.,
and Bernhard, S. A.
(1971)
Biochemistry
10,
4114-4120[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Nachmanson, D.,
and Wilson, I. B.
(1951)
Acta Enzymol.
12,
259-339
|
| 9.
|
Marcel, V.,
Gagnoux-Palacios, L.,
Pertuy, C.,
Masson, P.,
and Fournier, D.
(1998)
Biochem. J.
329,
329-334
|
| 10.
|
Stojan, J.,
Marcel, V.,
Estrada-Mondaca, S.,
Klaebe, A.,
Masson, P.,
and Fournier, D.
(1998)
FEBS Lett.
440,
85-88[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Stojan, J.,
Marcel, M.,
and Fournier, D.
(1999)
Chem. Biol. Interact.
119-120,
137-146
|
| 12.
|
Millar, D. B.,
Christopher, J. P.,
and Bishop, W. H.
(1979)
Biophys. Chem.
10,
147-151[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Kamaric, L.
(1982)
Period. Biol.
84,
143-146
|
| 14.
|
Johnson, C. D.,
and Russell, R. L.
(1983)
J. Neurochem.
41,
30-46[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Chaabihi, H.,
Fournier, D.,
Fedon, Y.,
Bossy, J. P.,
Ravallec, M.,
Devauchelle, G.,
and Cérutti, M.
(1994)
Biochem. Biophys. Res. Commun.
203,
734-742[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Estrada-Mondaca, S.,
and Fournier, D.
(1998)
Protein Exp. Purif.
12,
166-172[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Levy, D.,
and Ashani, Y.
(1986)
Biochem. Pharmacol.
35,
1079-1085[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Hall, L. M. C.,
and Spierer.
(1986)
EMBO J.
5,
2949-2954[Medline]
[Order article via Infotrieve]
|
| 19.
|
Stojan, J.
(1999)
J. Enzyme Inhib.
14,
193-201[Medline]
[Order article via Infotrieve]
|
| 20.
|
Ellman, G. L.,
Courtney, K. D.,
Andres, V.,
and Feathersone, R. M.
(1961)
Biochem. Pharmacol.
7,
88-95[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Aldrige, W. N.
(1950)
Biochem. J.
46,
451-456
|
| 22.
|
Ross, S.,
and Olivier, P.
(1959)
J. Phys. Chem.
63,
1671-1674[CrossRef]
|
| 23.
|
Cauet, G.,
Friboulet, A.,
and Thomas, D.
(1987)
Biochem. Cell Biol.
65,
529-535[Medline]
[Order article via Infotrieve]
|
| 24.
|
Fournier, D.,
Bergé, J. B.,
Cardoso de Almeida, M. L.,
and Bordier, C.
(1988)
J. Neurochem.
50,
1158-1163[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Haas, R.,
Marshall, T. C.,
and Rosenberry, T. L.
(1988)
Biochemistry
27,
6453-6457[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Devonshire, A.
(1975)
Biochem. J.
149,
463-469[Medline]
[Order article via Infotrieve]
|
| 27.
|
Radic, Z.,
Pickering, N. A.,
Vellom, D. C.,
Camp, S.,
and Taylor, P.
(1993)
Biochemistry
32,
12074-12084[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Cousin, X.,
Bon, S.,
Duval, N.,
Massoulié, J.,
and Bon, C.
(1996)
J. Biol. Chem.
271,
15099-15108[Abstract/Free Full Text]
|
| 29.
|
Loewenstein-Lichtenstein, Y.,
Click, D.,
Gluzman, N.,
Sternfeld, M.,
Zakut, H.,
and Soreq, H.
(1996)
Mol. Pharmacol.
50,
1423-1431[Abstract]
|
| 30.
|
Shafferman, A.,
Velan, B.,
Ordentlich, A.,
Kronman, C.,
Grosfeld, H.,
Leitner, M.,
Flashner, Y.,
Cohen, S.,
Barak, D.,
and Ariel, N.
(1992)
EMBO J.
11,
3561-3568[Medline]
[Order article via Infotrieve]
|
| 31.
|
Harel, M.,
Sussman, J. L.,
Krejci, E.,
Bon, S.,
Chanal, P.,
Massoulié, J.,
and Silman, I.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
10827-10831[Abstract/Free Full Text]
|
| 32.
|
Hopp, T. P.,
and Woods, K. R.
(1981)
Proc. Natl. Acad. Sci. U. S. A.
78,
3824-3828[Abstract/Free Full Text]
|
| 33.
|
Fraenkel, Y.,
Gershoni, J. M.,
and Navon, G.
(1994)
Biochemistry
33,
644-650[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Berman, H. A.,
Becktel, W.,
and Taylor, P.
(1981)
Biochemistry
20,
4803-4810[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Ordentlich, A.,
Barak, D.,
Kronman, C.,
Ariel, N.,
Segall, Y.,
Velan, B.,
and Shafferman, A.
(1995)
J. Biol. Chem.
270,
2082-2091[Abstract/Free Full Text]
|
| 36.
| Deleted in proof
|
| 37.
|
Szegletes, T.,
Mallender, W. D.,
and Rosenberry, T.
(1998)
Biochemistry
37,
4206-4216[CrossRef][Medline]
[Order article via Infotrieve]
|
| 38.
|
Szegletes, T.,
Mallender, W. D.,
Thomas, P. J.,
and Rosenberry, T.
(1999)
Biochemistry
38,
122-133[CrossRef][Medline]
[Order article via Infotrieve]
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
C. A. Rosenfeld and L. G. Sultatos
Concentration-Dependent Kinetics of Acetylcholinesterase Inhibition by the Organophosphate Paraoxon
Toxicol. Sci.,
April 1, 2006;
90(2):
460 - 469.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Boublik, P. Saint-Aguet, A. Lougarre, M. Arnaud, F. Villatte, S. Estrada-Mondaca, and D. Fournier
Acetylcholinesterase engineering for detection of insecticide residues
Protein Eng. Des. Sel.,
January 1, 2002;
15(1):
43 - 50.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Gillim, G. L. Gusella, J. Vargas Jr., D. Marras, M. E. Klotman, and A. Cara
Development of a Novel Screen for Protease Inhibitors
Clin. Vaccine Immunol.,
March 1, 2001;
8(2):
437 - 440.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Brochier, Y. Pontie, M. Willson, S. Estrada-Mondaca, J. Czaplicki, A. Klaebe, and D. Fournier
Involvement of Deacylation in Activation of Substrate Hydrolysis by Drosophila Acetylcholinesterase
J. Biol. Chem.,
May 18, 2001;
276(21):
18296 - 18302.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2000 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|